MOG-IgG associated disease Myelin oligodendrocyte glycoprotein Paediatric CNS inflammatory disorders Systematic review Treatment.Ĭopyright © 2021. RCTs with standardized outcomes are needed to confirm the safety and efficacy of current and new treatments. The inflammatory demyelinating disease subtypes in which MOG antibodies have been reported are monophasic acute disseminated encephalomyelitis (ADEM), ADEM followed by episodes of optic neuritis (ON), multiphasic demyelinating encephalomyelitis, and recurrent ON. However, the most frequently used medications are not those that have shown higher reduction in the annualised relapse rate in observational studies. In terms of clinical syndromes experienced at any point during the disease course, MOG-antibody positive patients were more likely to have experienced optic. Interpretation long-term treatment was reported mainly in relapsing MOGAD paediatric patients. The most frequently reported treatments were prolonged oral corticosteroids in 53% of the studies followed by azathioprine (51%), mycophenolate mofetil (45%), rituximab (41%) and periodic intravenous immunoglobulin (26%).

Long-term maintenance treatment was described by 53 studies mainly in relapsing disease course. The most commonly reported acute phase treatment was intravenous methylprednisolone in 88% followed by oral steroids in 67%, intravenous human immunoglobulin (IVIG) in 66% and plasma exchange in 33% of the studies. There were no randomized controlled trials (RCTs). A: Recently proposed diagnostic criteria for MOG IgG associated disorders must meet the 3 following criteria: 10 Laboratory finding: serum positive MOG-IgG by cell based assay Clinical findings of any of the following presentations: ADEM Optic neuritis, including chronic relapsing optic. Results We found 72 non-controlled studies (observational studies, case reports and expert recommendations). The search was conducted in Pubmed (MEDLINE) seeking articles of treatment of MOGAD in patients ≤ 18 years published between January 2012 and April 25th, 2020. based on the results of the mog-igg and aqp4-igg titrations for their serum and csf samples, patients were divided into the following 4 disease groups: mogad, aqp4-iggpositive nmosd, ms without these antibodies, and other conditions (e.g.

Method We followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Aim to perform a systematic review of the literature on treatment of paediatric patients with MOG-IgG associated disease (MOGAD).

Mog disease